Novavax reports progress on updated COVID-19 vaccine By Investing.com – Investing.com

GAITHERSBURG, Md. - Novavax , Inc. (NASDAQ:), a biotechnology company specializing in protein-based vaccines, announced its recent findings on an updated COVID-19 vaccine and the development of its influenza and COVID-19-Influenza Combination (CIC) vaccine candidates at the World Vaccine Congress in Washington, DC, which will take place from April 2 to 4, 2024.

The company shared new data from its ongoing research on the updated XBB.1.5 COVID-19 vaccine, NVX-CoV2601, in participants who had previously received mRNA vaccines. The findings indicated that the updated vaccine elicited strong neutralizing antibody responses against the XBB.1.5 subvariant and the currently circulating JN.1 subvariant.

Additionally, the safety and reactogenicity profile of NVX-CoV2601 was consistent with Novavax's original COVID-19 vaccine, NVX-CoV2373.

Novavax also highlighted differences in immunoglobulin (IgG) subclass responses and Fc-mediated effector functions observed between mRNA and protein-based COVID-19 vaccines. These details will be further discussed during the congress presentations.

The timeline for the Phase 3 trial of Novavax's influenza and CIC vaccine candidates is set to begin in the second half of 2024. The company will recap data to date and provide an overview of these vaccine candidates during the event.

Dr. Robert Walker, Chief Medical Officer at Novavax, is scheduled to contribute to a panel discussion titled "The Future of COVID-19 Vaccinations" on April 3. The panel will explore the development of broadly protective antigens and combination vaccines.

The presentations by Novavax at the World Vaccine Congress will include safety and immunogenicity of the Novavax XBB.1.5 SARS-CoV-2 vaccine, distinct differences in IgG4 switch and Fc effector functions between mRNA and Novavax protein-based COVID vaccination, and updates on the company's influenza and COVID-influenza combination vaccine.

Novavax's vaccine platform combines recombinant protein technology, nanoparticle technology, and its patented Matrix-M adjuvant to enhance immune responses. The company's product portfolio includes a COVID-19 vaccine, and its pipeline features a combination vaccine for COVID-19 and influenza. Novavax's adjuvant is also part of the R21/Matrix-M malaria vaccine developed by the University of Oxford and the Serum Institute of India.

This information is based on a press release statement from Novavax.

As Novavax, Inc. (NASDAQ:NVAX) continues to make strides in vaccine development, highlighted by their presentations at the World Vaccine Congress, the financial health and market performance of the company remain critical factors for investors.

With a market capitalization of $668.98 million, Novavax is navigating through a challenging period. The company's revenue for the last twelve months as of Q4 2023 stands at $983.71 million, yet it has experienced a significant revenue decline of 50.36% during the same period. This decline is mirrored in the quarterly figures, with an 18.48% drop in Q4 2023. These figures are crucial for investors to consider, as they reflect the company's current financial trajectory.

InvestingPro Tips reveal that Novavax holds more cash than debt on its balance sheet, which is a positive sign of liquidity. However, the company is quickly burning through cash, which, coupled with the fact that it does not pay a dividend, may raise concerns about its cash flow sustainability. Analysts also point out that Novavax is expected to see a sales decline in the current year and do not anticipate the company will be profitable this year. These insights suggest that while Novavax is advancing scientifically, it faces financial challenges that investors should monitor closely.

For those interested in a deeper analysis, there are additional InvestingPro Tips available, which can be accessed through the InvestingPro platform. For instance, investors might find it noteworthy that Novavax is trading at a low revenue valuation multiple and that the stock price has been quite volatile. To gain access to these insights and more, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. Currently, there are 11 additional tips listed on InvestingPro that can provide further guidance for those evaluating Novavax's financial health and investment potential.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Follow this link:

Novavax reports progress on updated COVID-19 vaccine By Investing.com - Investing.com